US company NorthWest
Biotherapeutics has been allowed
to sell its brain cancer drug in
Germany, before the treatment had
finished its late-stage trial.
The company received a “hospital
exemption” to provide its DCVax-L
to patients for treatment of any
glioma brain cancers, outside of the
company’s clinical trial.
The company said it could charge
full price for the treatment, and
that the approval period was
for five years, which could be
re-applied and re-issued once it
expired.
Patients could be from Germany
or elsewhere, Northwest
Biotherapeutics said.
The European Union had
encouraged the hospital
exemptions to foster use of
breakthrough biotechnology drugs
that had not yet won market
approval, Reuters reported.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Mar 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.